List of Contents

Critical Care Drugs Market Size, Share, and Trends 2024 to 2034

The global critical care drugs market size accounted for USD 1.16 billion in 2024, grew to USD 1.22 billion in 2025 and is expected to be worth around USD 1.91 billion by 2034, registering a CAGR of 5.12% between 2024 and 2034.

  • Last Updated : October 2024
  • Report Code : 5158
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Critical Care Drugs Market 

5.1. COVID-19 Landscape: Critical Care Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Critical Care Drugs Market, By Drug Type

8.1. Critical Care Drugs Market Revenue and Volume, By Drug Type, 2024-2034

8.1.1 Opioids

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Morphine

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Pethidine

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

8.1.4. Naloxone

8.1.4.1. Market Revenue and Volume Forecast (2021-2034)

8.1.5. Fentanyl

8.1.5.1. Market Revenue and Volume Forecast (2021-2034)

8.1.6. Benzodiazepines

8.1.6.1. Market Revenue and Volume Forecast (2021-2034)

8.1.7. Diazepam

8.1.7.1. Market Revenue and Volume Forecast (2021-2034)

8.1.8. Midazolam

8.1.8.1. Market Revenue and Volume Forecast (2021-2034)

8.1.9. Lorazepum

8.1.9.1. Market Revenue and Volume Forecast (2021-2034)

8.1.10. Flumazenil

8.1.10.1. Market Revenue and Volume Forecast (2021-2034)

8.1.11. Sedatives

8.1.11.1. Market Revenue and Volume Forecast (2021-2034)

8.1.12. Anesthetics

8.1.12.1. Market Revenue and Volume Forecast (2021-2034)

8.1.13. Others

8.1.13.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global Critical Care Drugs Market, By End-user

9.1. Critical Care Drugs Market Revenue and Volume, By End-user, 2024-2034

9.1.1. Intensive Care Unit (ICU)

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. Coronary Care Unit (CCU)

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. Operation Theatres

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

9.1.4. Trauma Centers

9.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global Critical Care Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.1.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.1.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.1.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.2.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.2.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.2.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.2.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.2.6.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.3.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.3.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.3.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.3.6.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.4.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.4.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.4.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.4.6.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.5.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)

10.5.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)

Chapter 11. Company Profiles

11.1. Pfizer Inc

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Abbott

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Cadila Pharmaceutica

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Cambrex Corporation

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Triveni Chemicals

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Haffkine Bio-Pharmaceutical Corporation Ltd

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Neon Laboratories Limited

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client